JP Morgan Chase
ZBIO

JP Morgan Chase’s Zenas BioPharma ZBIO Stock Holding History

JP Morgan Chase’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$458K Buy
25,109
+3,383
+16% +$75.9K ﹤0.01% 5087
2025
Q4 		$789K Buy
21,726
+15,178
+232% +$499K ﹤0.01% 4754
2025
Q3 		$145K Sell
6,548
-1,128
-15% -$18.4K ﹤0.01% 5702
2025
Q2 		$74.4K Buy
7,676
+409
+6% +$3.98K ﹤0.01% 5742
2025
Q1 		$57.4K Sell
7,267
-22,572
-76% -$177K ﹤0.01% 5829
2024
Q4 		$244K Buy
+29,839
New +$465K ﹤0.01% 5389

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

JP Morgan Chase's ZBIO Position: Q1 2026 in Review

JP Morgan Chase increased its Zenas BioPharma (ZBIO) stake by 16% in Q1 2026, buying an estimated $75.9K and bringing the position to 25,109 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #5087.

JP Morgan Chase first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $789K in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • JP Morgan Chase held 25,109 shares of Zenas BioPharma worth $458K as of Q1 2026.
  • JP Morgan Chase bought 3,383 Zenas BioPharma shares in Q1 2026, an estimated $75.9K.
  • Zenas BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5087 holding.
  • JP Morgan Chase first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • JP Morgan Chase's Zenas BioPharma position peaked at $789K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.